Roche/Chugai Blaze a Trail...But Will Anyone Follow?
Executive Summary
Roche and Chugai have entered new dealmaking territory. This is the first time a Western company has taken over a Japanese counterpart in one go, and on a friendly basis. The deal grants Chugai enough independence for it to save face, while allowing Roche to leapfrog into the top ten in Japan. As such, the deal should in theory provide a template for others. But in Japan few CEOs are as open-minded as Chugai's leader. Equally, few Western companies can boast Roche's aptitude for arm's-length management.
You may also be interested in...
The Rise Of Japanese Pharma Dealmakers
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
The Rise Of Japanese Pharma Dealmakers
Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.
Yamanouchi/Fujisawa Merger: Closing Japanese Options
The Yamanouchi/Fujisawa acquisition may be the most important transaction to have occured in Japan in decades--or will be if it goes through. One key element: the deal ends important merger options for mid-size Japanese companies, who had more or less closed off transaction possibilities with Western companies at least partly in the hope of being able to do an intra-Japan deal. Now the Western firms have decided to build their own Japanese infrastructure, leaving the mid-sized firms without the strategic flexibility they once thought they had.